Skip to content

Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities

Research output: Contribution to journalArticle

Original languageEnglish
Article numberdyx207
Number of pages12
JournalInternational Journal of Epidemiology
Early online date11 Oct 2017
StateE-pub ahead of print - 11 Oct 2017


Identification of unintended drug effects, specifically drug repurposing opportunities and adverse drug events, maximizes the benefit of a drug and protects the health of patients. However, current observational research methods are subject to several biases. These include confounding by indication, reverse causality, and missing data. We propose that Mendelian randomization (MR) offers a novel approach for the prediction of unintended drug effects. In particular, we advocate the synthesis of evidence from this method and other approaches, in the spirit of triangulation, to improve causal inferences concerning drug effects. MR addresses some of the limitations associated with the existing methods in this field. Furthermore, it can be applied either pre- or post-approval of the drug and could therefore prevent the potentially harmful exposure of patients in clinical trials and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is yet to be realized and could both help prevent adverse drug events and identify novel indications for existing drugs in the future.

    Research areas

  • Mendelian randomization, pharmacovigilance, drug repurposing, adverse drug events

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Oxford University Press at Please refer to any applicable terms of use of the publisher.

    Final published version, 478 KB, PDF-document

    License: CC BY



View research connections

Related faculties, schools or groups